89 related articles for article (PubMed ID: 25750287)
21. Targeting Wnt pathway in lymphoma and myeloma cells.
Schmidt M; Sievers E; Endo T; Lu D; Carson D; Schmidt-Wolf IG
Br J Haematol; 2009 Mar; 144(5):796-8. PubMed ID: 19036118
[No Abstract] [Full Text] [Related]
22. PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis.
Goel A; Dispenzieri A; Greipp PR; Witzig TE; Mesa RA; Russell SJ
Exp Hematol; 2005 Jul; 33(7):784-95. PubMed ID: 15963854
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model.
Kharaziha P; De Raeve H; Fristedt C; Li Q; Gruber A; Johnsson P; Kokaraki G; Panzar M; Laane E; Osterborg A; Zhivotovsky B; Jernberg-Wiklund H; Grandér D; Celsing F; Björkholm M; Vanderkerken K; Panaretakis T
Cancer Res; 2012 Oct; 72(20):5348-62. PubMed ID: 22952216
[TBL] [Abstract][Full Text] [Related]
24. The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma.
Khong T; Sharkey J; Spencer A
Haematologica; 2008 Jun; 93(6):860-9. PubMed ID: 18443271
[TBL] [Abstract][Full Text] [Related]
25. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.
Evans RP; Naber C; Steffler T; Checkland T; Maxwell CA; Keats JJ; Belch AR; Pilarski LM; Lai R; Reiman T
Br J Haematol; 2008 Feb; 140(3):295-302. PubMed ID: 18076711
[TBL] [Abstract][Full Text] [Related]
26. All-trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells.
Huang H; Wu D; Fu J; Chen G; Chang W; Chow HC; Leung AY; Liang R
Eur J Haematol; 2009 Sep; 83(3):191-202. PubMed ID: 19467017
[TBL] [Abstract][Full Text] [Related]
27. Proteasome inhibition: novel therapy for multiple myeloma.
Kaufman JL; Lonial S
Onkologie; 2006 Apr; 29(4):162-8. PubMed ID: 16601373
[TBL] [Abstract][Full Text] [Related]
28. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
Qin JZ; Ziffra J; Stennett L; Bodner B; Bonish BK; Chaturvedi V; Bennett F; Pollock PM; Trent JM; Hendrix MJ; Rizzo P; Miele L; Nickoloff BJ
Cancer Res; 2005 Jul; 65(14):6282-93. PubMed ID: 16024630
[TBL] [Abstract][Full Text] [Related]
29. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism.
Escoubet-Lozach L; Lin IL; Jensen-Pergakes K; Brady HA; Gandhi AK; Schafer PH; Muller GW; Worland PJ; Chan KW; Verhelle D
Cancer Res; 2009 Sep; 69(18):7347-56. PubMed ID: 19738071
[TBL] [Abstract][Full Text] [Related]
30. ShRNA-mediated Bmi-1 silencing sensitizes multiple myeloma cells to bortezomib.
Wu SQ; Xu ZZ; Niu WY; Huang HB; Zhan R
Int J Mol Med; 2014 Aug; 34(2):616-23. PubMed ID: 24913180
[TBL] [Abstract][Full Text] [Related]
31. Syringolin B-inspired proteasome inhibitor analogue TIR-203 exhibits enhanced biological activity in multiple myeloma and neuroblastoma.
Opoku-Ansah J; Ibarra-Rivera TR; Pirrung MC; Bachmann AS
Pharm Biol; 2012 Jan; 50(1):25-9. PubMed ID: 22196580
[TBL] [Abstract][Full Text] [Related]
32. Valproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell lines.
Schwartz C; Palissot V; Aouali N; Wack S; Brons NH; Leners B; Bosseler M; Berchem G
Int J Oncol; 2007 Mar; 30(3):573-82. PubMed ID: 17273758
[TBL] [Abstract][Full Text] [Related]
33. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
34. Eriocalyxin B induces apoptosis in lymphoma cells through multiple cellular signaling pathways.
Zhang YW; Jiang XX; Chen QS; Shi WY; Wang L; Sun HD; Shen ZX; Chen Z; Chen SJ; Zhao WL
Exp Hematol; 2010 Mar; 38(3):191-201. PubMed ID: 20045442
[TBL] [Abstract][Full Text] [Related]
35. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation.
Munemasa S; Sakai A; Kuroda Y; Okikawa Y; Katayama Y; Asaoku H; Kubo T; Shimose S; Kimura A
Int J Oncol; 2008 Jul; 33(1):129-36. PubMed ID: 18575758
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma.
Baumann P; Schneider L; Mandl-Weber S; Oduncu F; Schmidmaier R
Anticancer Drugs; 2012 Jan; 23(1):131-8. PubMed ID: 21959532
[TBL] [Abstract][Full Text] [Related]
37. Anti-proliferative and cytotoxic effects of Strychnos nux-vomica root extract on human multiple myeloma cell line - RPMI 8226.
Rao PS; Ramanadham M; Prasad MN
Food Chem Toxicol; 2009 Feb; 47(2):283-8. PubMed ID: 19027818
[TBL] [Abstract][Full Text] [Related]
38. Anti-proliferative effect of levamisole on human myeloma cell lines in vitro.
Ramanadham M; Nageshwari B
J Immunotoxicol; 2010; 7(4):327-32. PubMed ID: 20860474
[TBL] [Abstract][Full Text] [Related]
39. CD74 is expressed by multiple myeloma and is a promising target for therapy.
Burton JD; Ely S; Reddy PK; Stein R; Gold DV; Cardillo TM; Goldenberg DM
Clin Cancer Res; 2004 Oct; 10(19):6606-11. PubMed ID: 15475450
[TBL] [Abstract][Full Text] [Related]
40. Discovery, Development, and clinical applications of bortezomib.
Jung L; Holle L; Dalton WS
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]